全文获取类型
收费全文 | 708篇 |
免费 | 61篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 22篇 |
妇产科学 | 29篇 |
基础医学 | 85篇 |
口腔科学 | 47篇 |
临床医学 | 65篇 |
内科学 | 135篇 |
皮肤病学 | 29篇 |
神经病学 | 11篇 |
特种医学 | 99篇 |
外科学 | 95篇 |
综合类 | 35篇 |
预防医学 | 54篇 |
眼科学 | 7篇 |
药学 | 40篇 |
中国医学 | 1篇 |
肿瘤学 | 26篇 |
出版年
2023年 | 7篇 |
2020年 | 7篇 |
2018年 | 12篇 |
2017年 | 15篇 |
2016年 | 21篇 |
2015年 | 15篇 |
2014年 | 13篇 |
2013年 | 23篇 |
2012年 | 26篇 |
2011年 | 30篇 |
2010年 | 25篇 |
2009年 | 34篇 |
2008年 | 20篇 |
2007年 | 42篇 |
2006年 | 9篇 |
2005年 | 17篇 |
2004年 | 13篇 |
2003年 | 10篇 |
2002年 | 17篇 |
2001年 | 8篇 |
2000年 | 15篇 |
1999年 | 11篇 |
1998年 | 21篇 |
1997年 | 38篇 |
1996年 | 33篇 |
1995年 | 20篇 |
1994年 | 17篇 |
1993年 | 22篇 |
1992年 | 7篇 |
1991年 | 12篇 |
1990年 | 5篇 |
1989年 | 19篇 |
1988年 | 27篇 |
1987年 | 17篇 |
1986年 | 17篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 14篇 |
1982年 | 6篇 |
1981年 | 13篇 |
1980年 | 8篇 |
1978年 | 12篇 |
1977年 | 6篇 |
1976年 | 4篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1968年 | 6篇 |
1967年 | 4篇 |
1966年 | 7篇 |
1965年 | 4篇 |
排序方式: 共有786条查询结果,搜索用时 15 毫秒
1.
2.
Sally Urang Lorna Davis Charlotte Cram Elsberry Mary Kay Kozlowski 《Journal of Midwifery & Women's Health》1993,38(Z1):95s-99s
Fetal scalp blood sampling (FSBS), in conjunction with fetal heart rate monitoring, is a method of fetal surveillance that may avoid cesarean delivery of the healthy fetus or indicate the need for immediate delivery of a compromised fetus. Some researchers have recently begun to question the efficacy of FSBS. In this article, three nurse-midwives discuss FSBS as a tool in assessing fetal well-being during labor and consider whether FSBS is a nurse-midwifery procedure. 相似文献
3.
4.
The role of growth factors and cytokines in the impaired healing of chronic leg ulcers remains uncertain. The aim of this study was to determine whether changes in the amount and location of cytokines and growth factors may be associated with impaired healing in chronic leg ulcers. Biopsies from leg ulcers of 21 patients and from normal skin of nine healthy volunteers were examined immunohistochemically for selected growth factors and cytokines. Greater staining intensity was found in keratinocytes at the edges of ulcers compared to normal skin, or skin adjacent to the ulcers. Staining at the ulcer edge was more intense in nonhealing ulcers for only vascular endothelial growth factor and platelet-derived growth factor, whereas staining in the adjacent skin was more intense for all factors in the nonhealing phase. For all factors staining was cytoplasmic, suggesting production in these areas. This study shows up-regulation of the production of cytokines and growth factors in keratinocytes of chronic leg ulcers that is greater when the ulcers are nonhealing. 相似文献
5.
6.
Artificial dermis for major burns. A multi-center randomized clinical trial. 总被引:12,自引:0,他引:12
下载免费PDF全文
![点击此处可从《Annals of surgery》网站下载免费的PDF全文](/ch/ext_images/free.gif)
D Heimbach A Luterman J Burke A Cram D Herndon J Hunt M Jordan W McManus L Solem G Warden et al. 《Annals of surgery》1988,208(3):313-320
This communication presents an 11-center prospective randomized trial using the artificial dermis invented by Burke and Yannas. Patients with life-threatening burns who underwent primary excision and grafting within 7 days of injury had comparable sites randomized to receive either the artificial dermis (study site) or the investigator's usual skin grafting material (control site). Control materials were autograft, allograft, xenograft, or a synthetic dressing. Epidermal grafts were applied to the study site during a second operation, and surviving patients were followed for 1 year after grafting. One hundred thirty-nine sites on 106 patients were studied. Mean burn size was 46.5 +/- 15% mean total body surface (TBSA). Overall mortality was 13%, and mean hospital stay was 68 +/- 45 days. Median artificial dermis take was 80% compared with 95% for all comparative sites, but the take was equivalent to that of all nonautograft control materials. Results with the artificial dermis improved slightly as the investigators became more familiar with the material. Donor site thickness for the study site averaged .006' +/- .002' compared to .013' +/- .018' for control (p less than .0001) and the epidermal donor site healed an average of 4 days sooner (10 +/- 6 vs. 14 +/- 8 days) (p less than .0001). As the wounds matured during the first year, both patients and surgeons felt that both sites became more comparable in appearance and function. At the completion of the study, there was less hypertrophic scarring of the artificial dermis, and more patients preferred the artificial dermis to the control graft. Artificial dermis with an epidermal graft provides a permanent cover that is at least as satisfactory as currently available skin grafting techniques, and uses donor grafts that are thinner and donor sites that heal faster. 相似文献
7.
8.
9.
10.
Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. 总被引:1,自引:0,他引:1
Collins CE Benson MJ Burnham WR Rampton DS 《Alimentary pharmacology & therapeutics》1996,10(3):315-320
BACKGROUND: Inflammatory bowel disease is associated with increased mucosal release of eicosanoids. Among these, thromboxane A2 has been proposed as a possible inflammatory mediator; its suppression may be a useful therapeutic option. METHODS: Using a tissue incubation technique, we compared release of immunoreactive thromboxane B2 by colonic biopsies from patients with ulcerative colitis, Crohn's disease and controls, and assessed the inhibitory effect of picotamide, a thromboxane synthesis inhibitor-receptor antagonist, which has been widely used in Italy for management of ischaemic heart and cerebrovascular disease. RESULTS: Increased amounts of thromboxane B2 were released from biopsies from patients with active ulcerative colitis (median 238 pg/20 min/mg wet weight (interquartile range 147- 325), n = 12) and active Crohn's disease (252 (174-450), 6) compared with those from patients with quiescent ulcerative colitis (95 (61- 140), 12) or Crohn's disease (105 (57-201), 13), or controls (136 (64- 206), 8). Incubation with picotamide at concentrations between 100 microM and 1 mM reduced thromboxane B2 release (IC50 890 microM). CONCLUSION: Since increased thromboxane A2 production may have pathogenetic importance, thromboxane synthesis inhibitor-receptor antagonists such as picotamide merit therapeutic trial in the management of inflammatory bowel disease. 相似文献